Delving into the Latest Updates on WJ-Pure with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Respiratory DiseasesImmune System DiseasesNervous System Diseases+ [3]

Active Indication

Pulmonary Disease, Chronic ObstructiveAlzheimer DiseaseMuscular Dystrophy, Duchenne+ [1]

Inactive Indication

COVID-19Respiratory Distress Syndrome, Acute

Originator Organization

Vitti Labs LLC.

Active Organization

Vitti Labs LLC.

Inactive Organization-

Drug Highest PhaseIND Application

First Approval Date-

Regulation-

Login to view timeline

Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients.
The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. .

Start Date20 Mar 2025

Sponsor / Collaborator

Vitti Labs LLC.

100 Clinical Results associated with WJ-Pure

Login to view more data

100 Translational Medicine associated with WJ-Pure

Login to view more data

100 Patents (Medical) associated with WJ-Pure

Login to view more data

18

Literatures (Medical) associated with WJ-Pure

18 Sep 2024·Cancer Cell International

Enhanced anti-tumor efficacy of S3I-201 in breast cancer mouse model through Wharton jelly- exosome.

Article

Author: Salek Farrokhi, Amir ; Soudi, Sara ; Hosseini, Masoomeh ; Ezzeddini, Rana ; Hashemi, Seyed Mahmoud

OBJECTIVE:

Exosomes, membrane-enveloped vesicles found in various cell types, including Wharton's jelly mesenchymal stem cells, play a crucial role in intercellular communication and regulation. Their use as a cell-free nanotechnology and drug delivery system has attracted attention. Triple-negative breast cancer (TNBC) is a major global health problem and is characterized by a high mortality rate. This study investigates the potential of Wharton's Jelly mesenchymal stem cell-derived exosomes (WJ-Exo) as carriers of S3I-201 and their effects on STAT3 expression in breast cancer cell lines, and evaluates whether these exosomes can enhance the anti-tumor effect of S3I-201.

METHODS:

The filtered WJ-Exos were analyzed by Transmission Electron Microscopy (TEM), Scanning electron microscopy (SEM), Dynamic Light Scattering (DLS), flow cytometry, and Western blotting. These exosomes were then used for loading with S3I-201, resulting in the nano-formulation WJ-Exo(S3I-201). The effect of WJ-Exo(S3I-201) on 4T1 cancer cells was investigated in vitro using MTT assay, flow cytometry, wound healing assay, Western blotting and Quantitative Real-Time Polymerase chain reaction (qPCR) analysis. Finally, the therapeutic efficacy of the nano-formulation was investigated in vivo using a tumor-bearing mouse model.

RESULTS:

In vitro experiments showed that co-incubation of 4T1 cells with the nano-formulation resulted in a significant reduction in p-STAT3 levels, induction of apoptosis, modulation of Bcl-2, Bax and caspase-3 protein and gene expression, and inhibition of migration. In vivo, treatment of tumor-bearing mice with WJ-Exo(S3I-201) showed a strong antitumor effect that exceeded the efficacy observed in the S3I-201 group.

CONCLUSION:

Our results demonstrate that WJ-Exo is an effective carrier for targeting S3I-201 to tumor cells and enhances the therapeutic efficacy of S3I-201 in tumor-bearing mice.

13 Mar 2024·British medical bulletin

Wharton’s jelly and osteoarthritis of the knee

Review

Author: Potty, Anish G ; Maffulli, Nicola ; Aratikatla, Adarsh ; Gupta, Ashim ; Potti, Ishana A ; Gupta, Manu

Abstract:

Introduction:

The existing treatment modalities for knee osteoarthritis (OA) do not actually address the pathology. Biological therapies, including those using material derived from perinatal tissues, represent a ground-breaking approach to alleviating the symptoms of OA of the knee.

Source of data:

Current scientific literature published in PubMed (MEDLINE), Embase and Scopus databases. Trials registered in various clinical trial databases.

Areas of agreement:

Perinatal tissues including Wharton’s jelly (WJ) and associated mesenchymal stem cells (MSCs) can be used for the management of knee OA.

Areas of controversy:

The efficacy of WJ and associated MSCs in the management of knee OA is still controversial.

Growing points:

The use of WJ and associated MSCs in the management of knee OA is safe and appears to be effective.

Areas timely for developing research:

The present published evidence suggests that WJ tissue and associated MSCs offer an encouraging alternative for the management of knee OA. The published in vitro, preclinical and clinical investigations demonstrate the therapeutic potential of WJ and promote further research in this field to provide symptomatic relief to patients suffering from OA, aiming also to regenerate the osteoarthritic hyaline cartilage, with disease-modifying effects. Future adequately powered randomized controlled trials should be undertaken to establish whether WJ is helpful in the management of OA of the knee.

01 Dec 2022·BMC oral health

Efficiency of biofilm removal by combination of water jet and cold plasma: an in-vitro study

Article

Author: Kocher, Thomas ; Schlüter, Rabea ; Vilardell Scholten, Laura ; Eberhard, Christian ; Gerling, Torsten ; Seifert, Leo ; Holtfreter, Birte ; Pitchika, Vinay ; Matthes, Rutger ; Jablonowski, Lukasz

Abstract:

Background:

Peri-implantitis therapy is a major problem in implantology. Because of challenging rough implant surface and implant geometry, microorganisms can hide and survive in implant microstructures and impede debridement. We developed a new water jet (WJ) device and a new cold atmospheric pressure plasma (CAP) device to overcome these problems and investigated aspects of efficacy in vitro and safety with the aim to create the prerequisites for a clinical pilot study with these medical devices.

Methods:

We compared the efficiency of a single treatment with a WJ or curette and cotton swab (CC) without or with adjunctive use of CAP (WJ + CAP, CC + CAP) to remove biofilm in vitro from rough titanium discs. Treatment efficacy was evaluated by measuring turbidity up to 72 h for bacterial re-growth or spreading of osteoblast-like cells (MG-63) after 5 days with scanning electron microscopy. With respect to application safety, the WJ and CAP instruments were examined according to basic regulations for medical devices.

Results:

After 96 h of incubation all WJ and CC treated disks were turbid but 67% of WJ + CAP and 46% CC + CAP treated specimens were still clear. The increase in turbidity after WJ treatment was delayed by about 20 h compared to CC treatment. In combination with CAP the cell coverage significantly increased to 82% (WJ + CAP) or 72% (CC + CAP), compared to single treatment 11% (WJ) or 10% (CC).

Conclusion:

The newly developed water jet device effectively removes biofilm from rough titanium surfaces in vitro and, in combination with the new CAP device, biologically acceptable surfaces allow osteoblasts to grow. WJ in combination with CAP leads to cleaner surfaces than the usage of curette and cotton swabs with or without subsequent plasma treatment. Our next step will be a clinical pilot study with these new devices to assess the clinical healing process.

100 Deals associated with WJ-Pure

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 1	US	Vitti Labs LLC.	20 Mar 2025
Respiratory Distress Syndrome, Acute	Phase 1	US	Vitti Labs LLC.	20 Mar 2025
Pulmonary Disease, Chronic Obstructive	IND Application	US	Vitti Labs LLC.	30 Jan 2022
Alzheimer Disease	Preclinical	US	Vitti Labs LLC.	30 Jan 2022
Muscular Dystrophy, Duchenne	Preclinical	US	Vitti Labs LLC.	30 Jan 2022
Osteoarthritis	Preclinical	US	Vitti Labs LLC.	30 Jan 2022